Gapping up
Select pharma/biotech stocks trading higher following ASH/presentations:
- FULC +45.6%, NRIX +16.9%, ACLX +15.1%, ALXO +9.9%, DYN +8.1%, SLS +7.2%, WVE +6%, PRME +5.3%, ORIC +4.5%, AAPG +4.4%, SNDX +3.3%, BNTX +3%, EVAX +2.9%, BEAM +1.9%, INCY +1.7%, ADPT +1.5%, GMAB +0.9%
Other news:
- IMMX +19.6% (reports Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis; prices upsized $100 mln underwritten offering)
- KYMR +17.3% (to announce KT-621 BroADen Phase 1b Atopic dermatitis trial results on December 8 )
- OCUL +13.6% (plans accelerated NDA for AXPAXLI in wet AMD; intends to submit a new drug application for its product candidate AXPAXLI)
- BIDU +3.1% (confirms it is in the process of assessing proposed spin-off and listing)
- LYEL +3% (Presents New Clinical Data from Ongoing Trial of Ronde-Cel; files for 1.9 mln share common stock offering by selling shareholder)
- SNN +1.9% (unveils RISE strategy and sets 2028 financial targets)
- GLSI +1.8% (announces completion of enrollment in the open label arm of FLAMINGO-01)
- HOOD +1.7% (entered into agreements to acquire Indonesian brokerage PT Buana Capital Sekuritas and licensed digital asset trader PT Pedagang Aset Kripto)
- OBIO +1.6% (announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting)
- RZLT +1.4% (files mixed securities shelf offering)
- FRMI +1.1% (signs a definitive Electric Service Agreement with Southwestern Public Service Company; executes electric service agreement with Xcel Energy subsidiary for Project Matador)